ArticleLeukemia2014
Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.
Open access · bronzeAbstract read
In one paragraph
Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 59 citations in OpenAlex.
- In-silico identification of genetic variants associated with chronic lymphocytic leukemia for diagnostic and therapeutic applications.Scientific reports · 2026Article
- A novel application of XPO1 inhibition for the treatment of myelofibrosis.Blood neoplasia · 2024Review
- Zanubrutinib delays selinexor resistance evolution in biopsy sample-derived primary central nervous system lymphoma models.iScience · 2024Article
- Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma.Molecular oncology · 2023Article
- Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia.Scientific reports · 2023Article
- Deep thermal profiling for detection of functional proteoform groups.Nature chemical biology · 2023Article
- A general method for quantitative fractionation of mammalian cells.The Journal of cell biology · 2023Article
- Article
- Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation.Nature communications · 2023Article
- Therapeutics to harness the immune microenvironment in multiple myeloma.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Selinexor inhibits growth of patient derived chordomasFrontiers in oncology · 2022Article
- Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets.Cancers · 2021Review
- Review
- Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.Journal of neuro-oncology · 2020Article
- Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms.Exploration of targeted anti-tumor therapy · 2020Article
- Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects.OncoTargets and therapy · 2020Review
- Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.Cell death & disease · 2019Article
- Review
- Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Selinexor: First Global Approval.Drugs · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Y ZhongDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
D El-GamalDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
J A DubovskyDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
K A BeckwithDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
B K HarringtonDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
K E WilliamsDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
V M GoettlDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
S JhaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
X MoCenter for Biostatistics, The Ohio State University, Columbus, OH, USA.
J A JonesDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
J M FlynnDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
K J MaddocksDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
L A AndritsosDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
D McCauleyKaryopharm Therapeutics Inc., Natick, MA, USA.
S ShachamKaryopharm Therapeutics Inc., Natick, MA, USA.
M KauffmanKaryopharm Therapeutics Inc., Natick, MA, USA.
J C Byrd1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
R LapalombellaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
The Ohio State University · USKaryopharm Therapeutics (United States) · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MTranslational Training Grant in Experimental TherapeuticsK12CA133250 · NCI · OHIO STATE UNIVERSITY · PI WILLIAM E. CARSON, Rosa Lapalombella · 2008 to 2026
$15.0MSPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2MONOCOLOGY TRAINING GRANTT32CA009338 · NCI · OHIO STATE UNIVERSITY · PI BYRD, JOHN C., POLLOCK, RAPHAEL E. · 1985 to 2018
$8.3MNCI NIH HHS 1K12 CA133250NCI NIH HHS K12 CA133250NCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS T32 CA009338
Abstract
PubMed holds no abstract for this paper.
Indexed as
B-LymphocytesCell MovementCell ProliferationHumansHydrazinesLeukemia, Lymphocytic, Chronic, B-CellLymphocyte ActivationTriazolesHydrazinesselinexorTriazoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.